John W Jr GnannShow email address
Department of Medicine, The Medical University of South Carolina University Medical Center, Charleston, South Carolina | Department of Infectious Diseases, College of ...
Is this your profile? Claim your profile Copy URL Embed Link to your profile
John W Jr Gnann:Expert Impact
Concepts for whichJohn W Jr Gnannhas direct influence:Herpes zoster,Zoster vaccine,West nile,Postherpetic neuralgia,Genital herpes,Prosthetic valve endocarditis,Vaccine efficacy,Zoster pain.
John W Jr Gnann:KOL impact
Concepts related to the work of other authors for whichfor which John W Jr Gnann has influence:Herpes zoster,Postherpetic neuralgia,Simplex virus,Neuropathic pain,Antiviral agents,United states,Viral infections.
KOL Resume for John W Jr Gnann
Department of Medicine, The Medical University of South Carolina University Medical Center, Charleston, South Carolina
Department of Infectious Diseases, College of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA
Department of Medicine, Division of Infectious Diseases, Medical University of South Carolina, 135 Rutledge Avenue, MSC 752, 29425, Charleston, SC, USA
Emeritus Professor of Infectious Diseases, Brighton and Sussex Medical School, Brighton, UK
Medical University of South Carolina, Charleston, SC
Division of Infectious Diseases, Department of Internal Medicine, Medical University of South Carolina, Charleston, SC 29403, USA
University of Alabama at Birmingham
Medical University of South Carolina, Charleston, SC, USA
Birmingham Veterans Affairs Medical Center and University of Alabama at Birmingham
Medical University of South Carolina, Charleston
Division of Infectious Diseases, University of Alabama of Birmingham and Birmingham Veterans Administration Medical Center, Birmingham, Alabama, USA.
Birmingham Veterans Affairs Medical Center, Alabama
Division of Infectious Diseases, Department of Pediatrics, the University of Alabama at Birmingham, Nashville, Tennessee
Departments of Medicine, Pediatrics, and Microbiology, The University of Alabama at Birmingham and Birmingham VA Medical Center (Dr Gnann).
Birmingham VA Medical Center, Birmingham, Alabama, USA
Department of Medicine, Division of Infectious Diseases, University of Alabama, Birmingham
Department of Medicine, The University of Alabama, Birmingham
University of Alabama at Birmingham, Alabama
Departments of Medicine and Pediatrics, University of Alabama at Birmingham and the Veterans Administration Medical Center, Birmingham, AL
University of Alabama at Birmingham, Birmingham, AL, USA
Departments of Medicine and Microbiology, University of Alabama at Birmingham and Birmingham Veteran's Administration Medical Center, Los Angeles
Departments of Medicine and Microbiology, University of Alabama at Birmingham, 1600 7th Avenue South, ACC 616 Birmingham, Alabama, USA
Department of Pediatrics, Children's Hospital, University of Alabama at Birmingham, 153 Wallace Tumor Institute, 1824 6th Avenue, S. Birmingham, Alabama 35294‐3300, U.S.A.
University of Alabama at Birmingham, Alabama, Georgia
Departments of Pediatrics, Microbiology and Medicine, The University of Alabama at Birmingham, 1600 Seventh Avenue South, 616 Children’s Hospital, Birmingham, AL 35233, USA
Division of Infectious Diseases,
The University of Alabama at Birmingham, Antiviral Research Office, 309 Bevil Biomedical Research Building, 845 Nineteenth Street South, Birmingham, AL 35294-2710 USA
University of Alabama at Birmingham, Birmingham, AL
From the Departments of Pediatrics (R.J.W.), Microbiology (R.J.W., J.W.G.), and Medicine (R.J.W., J.W.G.), University of Alabama at Birmingham, Birmingham. Address reprint requests to Dr. Whitley at 653 Children's Hospital Tower, 1600 Seventh Ave. S., Birmingham, AL 35294–0011.
Departments of Medicine and Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama, USA
Department of Immunology, Scripps Clinic and Research Foundation, 10666 N. Torrey Pines Road, 92037, La Jolla, CA, USA
Departments of Pediatrics and Medicine, University of Alabama at Birmingham, Birmingham, Alabama USA
Department of Immunology, Research Institute of Scripps Clinic, La Jolla, California 92037.
Infectious Diseases Service, Department of Medicine, Madigan Army Medical Center, Tacoma, Washington USA
From the Infectious Diseases Service, Department of Medicine, Madigan Army Medical Center, Tacoma, Wash.
Departments of Medicine, Pediatrics and Microbiology, University of Alabama in Birmingham.
Departments of Pediatrics and Microbiology, Duke University Medical Center, Durham, North Carolina
|neurologic complications syndrome||#1|
|acute rash potential||#1|
|vzv retinitis persons||#1|
|primary exogenous contact||#1|
|ceftriaxone vitro activity||#1|
|primary infection varicella||#1|
|vzvspecific cellmediated immune||#1|
|latent vzv herpes||#1|
|incidence postherpetic neuralgia||#1|
|unusual complications vzv||#1|
|herpes zoster efforts||#1|
|persons current knowledge||#1|
|famciclovir famciclovir herpes||#1|
|variety neurologic complications||#1|
|zoster older adults||#1|
|older adults herpes||#1|
|new drugs activity||#1|
|declining varicellazoster virus||#1|
|herpes zoster variety||#1|
|reactivation latent vzv||#1|
|prevent herpes zoster||#1|
|Sign-in to see all concepts, it's free!|
Prominent publications by John W Jr Gnann
BACKGROUND: The incidence and severity of herpes zoster and postherpetic neuralgia increase with age in association with a progressive decline in cell-mediated immunity to varicella-zoster virus (VZV). We tested the hypothesis that vaccination against VZV would decrease the incidence, severity, or both of herpes zoster and postherpetic neuralgia among older adults.
METHODS: We enrolled 38,546 adults 60 years of age or older in a randomized, double-blind, placebo-controlled trial of an ...
|Known for Herpes Zoster | Postherpetic Neuralgia | Vaccine Recipients | Burden Illness | Pain Discomfort|
[ PUBLICATION ]
BACKGROUND: Herpes zoster (HZ) adversely affects individuals aged 50-59, but vaccine efficacy has not been assessed in this population. This study was designed to determine the efficacy, safety, and tolerability of zoster vaccine for preventing HZ in persons aged 50-59 years.
METHODS: This was a randomized, double-blind, placebo-controlled study of 22 439 subjects aged 50-59 years conducted in North America and Europe. Subjects were given 1 dose of licensed zoster vaccine (ZV) (Zostavax; ...
|Known for Zoster Vaccine | Persons Aged | 59 Years | North America | Incidence Hz|
A randomized, placebo‐controlled trial of oxycodone and of gabapentin for acute pain in herpes zoster
[ PUBLICATION ]
Although acute pain in patients with herpes zoster can be severe and has a substantial impact on health-related quality of life, there have been no randomized clinical trials of oral medications specifically for its ongoing treatment. A randomized clinical trial was conducted in which 87 subjects >or=50 years of age with herpes zoster within 6 calendar days of rash onset and with worst pain in the past 24h >or=3 on a 0-10 rating scale initiated 7 days of treatment with famciclovir in ...
|Known for Acute Pain | Herpes Zoster | Gabapentin Placebo | Opioid Clinical Trials | Healthrelated Quality|
[ PUBLICATION ]
Herpes zoster causes substantial morbidity, especially among older adults. Although the acute cutaneous manifestations can be painful and troublesome, the most important consequence of herpes zoster (shingles) is the chronic pain syndrome known as postherpetic neuralgia (PHN). Previous studies have suggested that declining varicella-zoster virus (VZV)-specific cell-mediated immune (CMI) responses account for the increased frequency of herpes zoster seen in older adults. This led to the ...
|Known for Herpes Zoster | Postherpetic Neuralgia | Vaccine Recipients | Shingles Prevention Study | Randomized Controlled|
Randomized Controlled Multicenter Trial of Aerosolized Ribavirin for Respiratory Syncytial Virus Upper Respiratory Tract Infection in Hematopoietic Cell Transplant Recipients
[ PUBLICATION ]
BACKGROUND: Respiratory syncytial virus infection of the upper airways may progress to fatal pneumonia in hematopoietic cell transplant recipients. The safety and efficacy of aerosolized ribavirin in preventing disease progression is unknown.
METHODS: In a multicenter prospective trial, hematopoietic cell transplant recipients with respiratory syncytial virus infection of the upper airways were randomized to receive ribavirin (2 g 3 times daily) or supportive care for 10 days. The ...
|Known for Aerosolized Ribavirin | Syncytial Virus | Transplant Recipients | Respiratory Tract | Viral Load|
[ PUBLICATION ]
BACKGROUND: The Shingles Prevention Study (SPS) demonstrated zoster vaccine efficacy through 4 years postvaccination. A Short-Term Persistence Substudy (STPS) demonstrated persistence of vaccine efficacy for at least 5 years. A Long-Term Persistence Substudy (LTPS) was undertaken to further assess vaccine efficacy in SPS vaccine recipients followed for up to 11 years postvaccination. Study outcomes were assessed for the entire LTPS period and for each year from 7 to 11 years ...
|Known for Vaccine Efficacy | Incidence Hz | Zoster Herpes | 5 Years | Term Persistence|
[ PUBLICATION ]
Accurate evaluation of pain plays a critical role in identifying new interventions for the treatment and prevention of herpes zoster and postherpetic neuralgia (PHN). Different types of pain and other sensory symptoms are found in patients with herpes zoster, and these vary greatly with respect to their presence, location, duration, intensity, and quality. The results of recent studies of herpes zoster and PHN and the development of new methods for assessing neuropathic pain provide a ...
|Known for Herpes Zoster | Postherpetic Neuralgia | Neuropathic Pain | New Interventions | Treatment Prevention|
BACKGROUND: After completion of the Shingles Prevention Study (SPS; Department of Veterans Affairs Cooperative Studies Program Number 403), SPS participants who had initially received placebo were offered investigational zoster vaccine without charge. This provided an opportunity to determine the relative safety of zoster vaccine in older adults following documented herpes zoster (HZ).
METHODS: A total of 13 681 SPS placebo recipients who elected to receive zoster vaccine were followed ...
|Known for Zoster Vaccine | Shingles Prevention Study | Aged 80 | Placebo Recipients | Female Herpes|
West Nile virus neuroinvasive disease: neurological manifestations and prospective longitudinal outcomes
[ PUBLICATION ]
BACKGROUND: West Nile Virus (WNV) is a mosquito-borne flavivirus that has caused ongoing seasonal epidemics in the United States since 1999. It is estimated that ≤1% of WNV-infected patients will develop neuroinvasive disease (West Nile encephalitis and/or myelitis) that can result in debilitating morbidities and long-term sequelae. It is essential to collect longitudinal information about the recovery process and to characterize predicative factors that may assist in therapeutic ...
|Known for West Nile | Neuroinvasive Disease | Neurological Manifestations | Virus Wnv | Longterm Sequelae|
Varicella-zoster virus (VZV) is the etiologic agent of varicella (primary infection) and herpes zoster (reactivation of latent infection). Although varicella is most often a relatively benign and self-limited childhood illness, the disease can be associated with a variety of serious and potentially lethal complications in both immunocompetent and immunocompromised persons. One complication of varicella that appears to be increasing in frequency is serious bacterial soft tissue infections ...
|Known for Atypical Presentations | Zoster Virus | Neurologic Complications | Pregnant Women | Primary Infection|